Cartesian Therapeutics (RNAC) Receivables - Other (2020 - 2024)
Historic Receivables - Other for Cartesian Therapeutics (RNAC) over the last 5 years, with Q3 2024 value amounting to $980000.0.
- Cartesian Therapeutics' Receivables - Other fell 4773.33% to $980000.0 in Q3 2024 from the same period last year, while for Sep 2024 it was $980000.0, marking a year-over-year decrease of 4773.33%. This contributed to the annual value of $3.0 million for FY2023, which is 572.42% down from last year.
- Cartesian Therapeutics' Receivables - Other amounted to $980000.0 in Q3 2024, which was down 4773.33% from $3.5 million recorded in Q2 2024.
- Cartesian Therapeutics' Receivables - Other's 5-year high stood at $3.5 million during Q2 2024, with a 5-year trough of $980000.0 in Q3 2024.
- For the 5-year period, Cartesian Therapeutics' Receivables - Other averaged around $1.8 million, with its median value being $1.5 million (2020).
- Within the past 5 years, the most significant YoY rise in Cartesian Therapeutics' Receivables - Other was 22909.95% (2024), while the steepest drop was 4773.33% (2024).
- Cartesian Therapeutics' Receivables - Other (Quarter) stood at $1.4 million in 2020, then dropped by 28.57% to $1.0 million in 2021, then skyrocketed by 216.2% to $3.2 million in 2022, then dropped by 5.72% to $3.0 million in 2023, then crashed by 67.13% to $980000.0 in 2024.
- Its Receivables - Other stands at $980000.0 for Q3 2024, versus $3.5 million for Q2 2024 and $2.4 million for Q1 2024.